Health Condition 1: K638- Other specified diseases of intestine
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
MVR Cancer Centre and Research Institute
Eligibility
Inclusion criteria
Inclusion criteria: All patients aged 18 years and above receiving chemotherapy for gastric and colorectal malignancies in neoadjuvant/adjuvant/palliative setting.
Exclusion criteria
Exclusion criteria: All patients who received prior chemotherapy with proven hepatic side effects. Patients with established chronic liver disease by imaging or intraoperatively– CPC B/C. All cases without a definite pathologic diagnosis All cases where relevant data is unavailable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage incidence of chemotherapy induced liver injury in patients receiving treatment for gastrointestinal malignancies.Timepoint: Evaluation will be done at baseline, 3 months after chemotherapy and at the end of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe the various patterns of hepatotoxicity associated with chemotherapy. Timepoint: Evaluation will be done at baseline, 3 months after chemotherapy and at the end of treatment;To compare incidence of hepatotoxicity associated with various chemotherapy regimens used in gastrointestinal malignancies.Timepoint: Evaluation will be done at baseline, 3 months after chemotherapy and at the end of treatment;To study patient, tumor and therapy related independent risk factors that can hasten the development of chemotherapy induced liver injury.Timepoint: Evaluation will be done at baseline, 3 months after chemotherapy and at the end of treatment | — |
Countries
India
Contacts
Public ContactDr Abhijith P B
MVR Cancer Centre and Research Institute
Outcome results
None listed